How would you manage patients with TNBC who achieve a pCR with neoadjuvant KEYNOTE-522 regimen, but develop isolated chest wall recurrence soon after completing neoadjuvant treatment?

Community
Company
News
Contact Us
Sign in

Topics: Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • Yale • Triple negative • NCI-CCC Breast Tumor Board Question

Would you provide adjuvant therapy? Palliative therapy?

No evidence of distance metastases.

Related Questions

For patients with metastatic HER2-null (IHC 0+) breast cancer, do you offer trastuzumab deruxtecan based on the DAISY trial results?

What is your preferred adjuvant chemotherapy regimen for a patient with local recurrence of TNBC two years after completing neoadjuvant ddAC-T who declined prior adjuvant capecitabine?

In light of SABCS 2022, will you use BCI to guide OFS recommendation in the adjuvant setting?

How do you incorporate ctDNA in the management of metastatic breast cancer?

In light of SABCS 2022, when will you opt for a CDK 4/6 inhibitor plus AI instead of chemotherapy in patients with metastatic HR-positive HER2-negative breast cancer with visceral crisis?

In what circumstances would you stop therapy for patients with metastatic HER2+ breast cancer with long-term complete response to HER2-directed therapy?

How do you manage adjuvant endocrine therapy for microinvasive HR-positive disease measuring >=1mm in extension?

In which situations do you consider post-mastectomy radiation therapy when the patient has a localized node-positive breast cancer with a complete nodal response and minimal residual disease in the breast post-neoadjuvant chemotherapy?

How do you approach initial treatment of unresectable, locally advanced ER+, HER2-negative male breast cancer?

Would you recommend axillary lymph node dissection in a pre-menopausal woman with ER+ PR+ HER2- IDC, s/p lumpectomy and SLN with pT1c pN1 cM0 disease, where 2 sentinel nodes are positive for macrometastasis and 1 SN is positive for micrometastasis?